Your browser doesn't support javascript.
loading
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Cannon, Christopher P; Gropper, Savion; Bhatt, Deepak L; Ellis, Stephen G; Kimura, Takeshi; Lip, Gregory Y H; Steg, Ph Gabriel; Ten Berg, Jurriën M; Manassie, Jenny; Kreuzer, Jörg; Blatchford, Jon; Massaro, Joseph M; Brueckmann, Martina; Ferreiros Ripoll, Ernesto; Oldgren, Jonas; Hohnloser, Stefan H.
Afiliação
  • Cannon CP; Harvard Clinical Research Institute, Boston, Massachusetts. christopher.cannon@hcri.harvard.edu.
  • Gropper S; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. christopher.cannon@hcri.harvard.edu.
  • Bhatt DL; Harvard Medical School, Boston, Massachusetts. christopher.cannon@hcri.harvard.edu.
  • Ellis SG; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
  • Kimura T; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
  • Lip GY; Harvard Medical School, Boston, Massachusetts.
  • Steg PG; Cleveland Clinic, Cleveland, Ohio.
  • Ten Berg JM; Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Manassie J; University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
  • Kreuzer J; FACT (French Alliance for Cardiovascular Trials), an F-CRIN network, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université Paris-Diderot, Sorbonne Paris-Cité, INSERM U-1148, Paris, France.
  • Blatchford J; NHLI Imperial College, ICMS Royal Brompton Hospital, London, United Kingdom.
  • Massaro JM; St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Brueckmann M; Medical Division Boehringer Ingelheim Ltd, Bracknell, Berkshire, United Kingdom.
  • Ferreiros Ripoll E; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
  • Oldgren J; Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
  • Hohnloser SH; Medical Division Boehringer Ingelheim Ltd, Bracknell, Berkshire, United Kingdom.
Clin Cardiol ; 39(10): 555-564, 2016 Oct.
Article em En | MEDLINE | ID: mdl-27565018
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Varfarina / Doença da Artéria Coronariana / Inibidores da Agregação Plaquetária / Stents / Antitrombinas / Antagonistas do Receptor Purinérgico P2Y / Intervenção Coronária Percutânea / Dabigatrana / Anticoagulantes Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cardiol Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Varfarina / Doença da Artéria Coronariana / Inibidores da Agregação Plaquetária / Stents / Antitrombinas / Antagonistas do Receptor Purinérgico P2Y / Intervenção Coronária Percutânea / Dabigatrana / Anticoagulantes Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cardiol Ano de publicação: 2016 Tipo de documento: Article